Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year […]
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year […]
